CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness

Frontiers in Immunology

Abstract

Chemotherapy is one of the important clinical treatments for malignant tumors, but primary or acquired chemotherapy resistance significantly limits patient benefits. Programmed death ligand 1 (PD-L1) has been reported to be regulated by chemotherapy and to contribute to chemotherapy resistance.

The paper

Runqiu Chen, Xiaoyu Pang, Fanglin Li,

Shanna Wu, Yiting Wang, Xinhang Zheng, Yaqi Zhao, Fengru Qiu, Liying Chen, Fengyu Du, Chen Chen, Rong Zhang, Zhiying Li, Yiru Long, Likun Gong,

Meiqing Feng

Fudan University

Frontiers in Immunology · 14 Sep 2026 · CC BY

doi.org/10.3389/fimmu.2026.1886034 PubMed 42807306

CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness

Abstract

The paper

Nicotinamide riboside did not improve early Parkinson disease

Periodic red light exposure eases cellular aging in mice

More daily steps modestly improved one thinking test score

Restricting eating hours led to lasting fat loss in flies

CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness

Abstract

The paper

More in Interventions